gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas

  • End date
    Jun 21, 2024
  • participants needed
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 21 January 2021


Patients with 1p/19q-codeleted anaplastic gliomas treated with RT + PCV are at risk of neurocognitive deterioration. Treating these patients with PCV alone (could reduce the risk of neurocognitive deterioration without impairing overall survival.


Multicentric, Randomized phase III study (1:1), Population: newly diagnosed 1p/19-codeleted anaplastic gliomas, Primary objective: To determine whether treating newly diagnosed 1p/19q-codeleted anaplastic gliomas with PCV alone can increase overall survival without neurocognitive deterioration Control group: radiotherapy followed by 6 cycles of PCV chemotherapy. Experimental group: 6 cycles of PCV chemotherapy (radiotherapy being deferred at the time of progression).

Number of centres participating: the 31 centers of the POLA network Recruitment duration: 7 years, the accrual rate being 40 patients per year, and patients are followed-up until the end of the trial.

Condition Anaplastic Gliomas With 1p/19q Codeletion, Anaplastic Gliomas With 1p/19q Codeletion
Treatment PCV chemotherapy alone, Radiotherapy+PCV chemotherapy
Clinical Study IdentifierNCT02444000
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on21 January 2021


Yes No Not Sure

Inclusion Criteria

Histological confirmation of anaplastic glioma by central pathological review
Tumor is co-deleted for 1p and 19q
Age 18 years of age
Newly diagnosed and 3 months from surgical diagnosis
Willing and able to complete neurocognitive examination and the QOL
Karnofsky performance status 60
The following laboratory values obtained 21 days prior to registration
Absolute neutrophil count (ANC) 1500 /mm3
Platelet count 100,000 / mm3
Hemoglobin > 9.0 g/dL
Total bilirubin 1.5 x upper limit of normal (ULN)
Negative serum or urine pregnancy test done 7 days prior to registration, for women of childbearing potential only
Provide informed written consent

Exclusion Criteria

Pregnant and nursing women
Men or women of childbearing potential who are unwilling to employ adequate contraception during this study and for up to 6 months following the completion of PCV
Received any prior radiation therapy or chemotherapy for any CNS neoplasm
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note